​

Janux Therapeutics (JANX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

JANX Stock Forecast

Janux Therapeutics (JANX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $57.25, with a high of $72.00 and a low of $45.00. This represents a 109.32% increase from the last price of $27.35.

$10 $23 $36 $49 $62 $75 High: $72 Avg: $57.25 Low: $45 Last Closed Price: $27.35

JANX Stock Rating

Janux Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (88.89%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 8 Strong Sell Sell Hold Buy Strong Buy

JANX Price Target Upside V Benchmarks

TypeNameUpside
StockJanux Therapeutics109.32%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-37
Avg Price Target-$54.67$63.71
Last Closing Price$27.35$27.35$27.35
Upside/Downside-99.89%132.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25414---18
Sep, 25311---14
Aug, 252111--14
Jul, 251111--13
Jun, 251111--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2025Barclays$47.00$23.41100.77%71.85%
Sep 10, 2025Stifel Nicolaus$45.00$24.3185.11%64.53%
Sep 03, 2025Brad CaninoGuggenheim$72.00$23.04212.50%163.25%
Jul 11, 2025Sean McCutcheonRaymond James$65.00$25.15158.45%137.66%
Feb 28, 2025Scotiabank$41.00$32.8924.66%49.91%
Feb 28, 2025Wedbush$76.00$32.89131.07%177.88%
Dec 03, 2024Justin ZelinBTIG$100.00$40.18148.88%265.63%
Oct 24, 2024David DaiUBS$69.00$51.7533.33%152.29%
Sep 05, 2024Bradley CaninoStifel Nicolaus$70.00$43.7160.15%155.94%
Aug 09, 2024George FarmerScotiabank$42.00$36.4915.10%53.56%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2025BarclaysOverweightinitialise
Sep 03, 2025GuggenheimBuyinitialise
Aug 18, 2025Piper SandlerOverweightinitialise
Jul 11, 2025Raymond JamesOutperforminitialise
Dec 03, 2024BTIGBuyBuyhold
Oct 24, 2024WedbushSector PerformSector Performhold
Oct 24, 2024UBSBuyinitialise
Sep 06, 2024ScotiabankUnderperformUnderperformhold
Aug 09, 2024WedbushSector PerformSector Performhold
Aug 09, 2024ScotiabankSector PerformSector Performhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.79$-1.31$-1.32$-1.28----
Avg Forecast$-1.25$-1.65$-1.52$-1.42$-1.93$-2.55$-3.24$-2.59
High Forecast$-1.10$-1.55$-1.37$-1.32$-1.19$-1.13$-1.19$-2.59
Low Forecast$-1.54$-2.02$-1.70$-1.66$-3.06$-6.06$-5.89$-2.59
Surprise %-36.80%-20.61%-13.16%-9.86%----

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.64M$8.61M$8.08M$10.59M----
Avg Forecast$2.45M$6.58M$6.37M$12.30M$5.32M$12.84M$10.29M$98.70M
High Forecast$2.89M$7.72M$6.78M$12.65M$5.54M$12.84M$10.29M$98.70M
Low Forecast$2.23M$6.29M$5.71M$12.18M$5.10M$12.84M$10.29M$98.70M
Surprise %48.61%30.98%26.96%-13.90%----

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-32.56M$-54.15M$-58.29M$-68.99M----
Avg Forecast$-54.91M$-72.41M$-67.69M$-60.54M$-116.23M$-162.08M$-218.30M$-113.90M
High Forecast$-48.63M$-68.27M$-60.42M$-57.94M$-52.39M$-49.62M$-52.54M$-113.90M
Low Forecast$-67.96M$-88.78M$-74.97M$-72.88M$-134.77M$-266.81M$-259.22M$-113.90M
Surprise %-40.71%-25.21%-13.89%13.97%----

JANX Forecast FAQ

Is Janux Therapeutics stock a buy?

Janux Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Janux Therapeutics is a favorable investment for most analysts.

What is Janux Therapeutics's price target?

Janux Therapeutics's price target, set by 9 Wall Street analysts, averages $57.25 over the next 12 months. The price target range spans from $45 at the low end to $72 at the high end, suggesting a potential 109.32% change from the previous closing price of $27.35.

How does Janux Therapeutics stock forecast compare to its benchmarks?

Janux Therapeutics's stock forecast shows a 109.32% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Janux Therapeutics over the past three months?

  • October 2025: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 21.43% Strong Buy, 78.57% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 14.29% Strong Buy, 78.57% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.

What is Janux Therapeutics’s EPS forecast?

Janux Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.93, marking a 50.78% increase from the reported $-1.28 in 2024. Estimates for the following years are $-2.55 in 2026, $-3.24 in 2027, and $-2.59 in 2028.

What is Janux Therapeutics’s revenue forecast?

Janux Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $5.32M, reflecting a -49.78% decrease from the reported $10.59M in 2024. The forecast for 2026 is $12.84M, followed by $10.29M for 2027, and $98.7M for 2028.

What is Janux Therapeutics’s net income forecast?

Janux Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-116M, representing an 68.47% increase from the reported $-68.994M in 2024. Projections indicate $-162M in 2026, $-218M in 2027, and $-114M in 2028.